Semi-parametric Empirical Bayes Method for Multiplet Detection in snATAC-seq with Probabilistic Multi-omic Integration

preprint OA: closed CC-BY-4.0
📄 Open PDF Full text JSON View at publisher

Abstract

Multiplets, formed when multiple cells are captured in a droplet, produce hybrid molecular profiles that confound single-cell analyses. Detecting multiplets in single-nucleus ATAC-seq (snATAC-seq) data is particularly challenging due to sparsity and overdispersion of chromatin accessibility measurements. We introduce SEBULA, a semi-parametric empirical Bayes model that yields well-calibrated posterior probabilities for multiplet detection, enabling principled false discovery rate control. SEBULA also integrates probabilistic evidence with complementary signals from other modalities, such as scRNA-seq. Benchmarking on simulations and seven annotated trimodal DOGMA-seq datasets demonstrates SEBULA’s superior performance. The open-source software is computationally efficient.
Full text 1,168 characters · extracted from oa-doi-fallback · click to expand
Abstract Multiplets, formed when multiple cells are captured in a droplet, produce hybrid molecular profiles that confound single-cell analyses. Detecting multiplets in single-nucleus ATAC-seq (snATAC-seq) data is particularly challenging due to sparsity and overdispersion of chromatin accessibility measurements. We introduce SEBULA, a semi-parametric empirical Bayes model that yields well-calibrated posterior probabilities for multiplet detection, enabling principled false discovery rate control. SEBULA also integrates probabilistic evidence with complementary signals from other modalities, such as scRNA-seq. Benchmarking on simulations and seven annotated trimodal DOGMA-seq datasets demonstrates SEBULA’s superior performance. The open-source software is computationally efficient. Competing Interest Statement JEG has served as a consultant to AbbVie, Eli Lilly, Almirall, Celgene, BMS, Janssen, Prometheus, TimberPharma, Galderma, Novatis, MiRagen, AnaptysBio and has received research support from AbbVie, SunPharma, Eli Lilly, Kyowa Kirin, Almirall, Celgene, BMS,Janssen, Prometheus, and TimberPharma. LCT has received support from Galderma and Janssen.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-4.0